No quarterly revenue total was found in MiNK Therapeutics, Inc.'s SEC filings.
MiNK Therapeutics, Inc. (INKT) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances).
Revenue
—
Net income
$-3.13M
+26.2% vs year-ago quarter
Operating cash flow
$-2.08M
-32.7% vs year-ago quarter
Free cash flow
—
EPS
$-0.62
+41.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
5.10M
+12.8% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- INKT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1840229
- Former names
- AgenTus Therapeutics, Inc. (until Mar 18, 2021); AgenTus Therapeutics, Inc. (until Mar 18, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$3.2M | -$2.9M | -$2.7M | -$3.2M | -$4.1M |
| Net income | -$3.1M | -$2.7M | -$2.6M | -$2.9M | -$4.2M |
| Diluted EPS | -$0.62 | -$0.57 | -$0.56 | -$0.65 | -$1.06 |
| Operating cash flow | -$2.1M | -$1.7M | -$2.1M | -$941,348 | -$1.6M |
| Total assets | $9.6M | $10.4M | $14.2M | $15.0M | $2.5M |
| Stockholders' equity | -$14.0M | -$12.7M | -$14.2M | -$13.5M | -$25.2M |
| Cash and investments | $8.8M | $9.5M | $13.4M | $9.5M | $1.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2026 | Jun 17, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 15, 2026 | May 15, 2026 |
| ARS | Annual report to shareholders | Apr 30, 2026 | Dec 31, 2025 |
All 265 MiNK Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.